# PRIMUS 001

Source: https://onco.cc/trials/primus-001/  
OnCo record `primus-001` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PRIMUS 001 is the flagship trial of the UK Precision-Panc programme, comparing a new oxaliplatin, fluorouracil and nab-paclitaxel combination with standard nab-paclitaxel and gemcitabine at 30 NHS hospitals from Aberdeen to Plymouth while collecting tumour DNA to find who benefits from which chemotherapy.

## Summary

PRIMUS 001 (ISRCTN75002153, NCT04151277) opened in November 2017 and randomises patients with metastatic pancreatic cancer to FOLFOX-A or nab-paclitaxel plus gemcitabine with G-CSF support, with progression-free survival as the primary endpoint and a biomarker programme run through Precision-Panc's molecular profiling. The registry lists 500 participants (estimated), 30 UK sites (Aberdeen, Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cottingham, Dundee, Edinburgh, Glasgow, Huddersfield, Inverness, Leeds, Liverpool, Guy's and Imperial in London among them), a primary completion date of December 2025 and a status of unknown because the record has not been verified since; no results were found in Europe PMC on 24 September 2026. Its siblings PRIMUS 002 (neoadjuvant chemotherapy for resectable disease) and PRIMUS 004 (biomarker-directed second-line platform) are registered with ISRCTN.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: PRIMUS-001; PRIMUS001; Precision-Panc PRIMUS 001
- Registry id: NCT04151277
- Phase: 2
- Setting: Metastatic pancreatic cancer at 30 UK hospitals: FOLFOX with nab-paclitaxel (FOLFOX-A) against nab-paclitaxel with gemcitabine, an adaptive randomised phase 2 with integrated biomarker evaluation and progression-free survival as the primary endpoint
- Sponsor: NHS Greater Glasgow and Clyde and the University of Glasgow (Precision-Panc)
- Enrolled: 500

## Notes

- UK sites (registry, 30): Aberdeen Royal Infirmary; Northern Ireland Cancer Centre Belfast; Queen Elizabeth Hospital Birmingham; Royal Bournemouth; Bristol Oncology Centre; Addenbrooke's Cambridge; Castle Hill Cottingham; Ninewells Dundee; Western General Edinburgh; Beatson Glasgow; Huddersfield Royal Infirmary; Raigmore Inverness; St James's Leeds; Clatterbridge Liverpool; Guy's and Imperial College London, and others.

## Sources

- ClinicalTrials.gov NCT04151277: https://clinicaltrials.gov/study/NCT04151277
- ISRCTN75002153: PRIMUS 001: https://www.isrctn.com/ISRCTN75002153

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- institutions: [Cancer Research UK](https://onco.cc/institutions/cruk/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/primus-001.json